Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.
This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS). TI is a noninvasive brain stimulation technique that uses two high-frequency electrical currents with slightly different frequencies to generate a lower-frequency modulation at a targeted deep brain region.
A total of 20 patients with TRS will receive 130-Hz TI stimulation targeting the anterior limb of the internal capsule (ALIC). Stimulation will be delivered at a total current intensity of 4 mA for 5 consecutive days, with four 40-minute sessions per day. Participants will continue their stable antipsychotic medication regimen during the study.
Clinical symptoms, cognitive function, social functioning, and safety will be assessed before treatment, after completion of the 5-day treatment course, and at a 2-week follow-up. The primary clinical outcome is the change in the Positive and Negative Syndrome Scale (PANSS) total score. Secondary assessments include PANSS subscale scores, the MATRICS Consensus Cognitive Battery (MCCB), Calgary Depression Scale for Schizophrenia (CDSS), Personal and Social Performance Scale (PSP), and Clinical Global Impression (CGI). Safety will be evaluated through daily monitoring of treatment-related discomfort and adverse events.
Magnetic resonance imaging (MRI) will also be performed before and after treatment to explore treatment-related changes in brain structure, functional activity, functional connectivity, activation, and cerebral blood flow. The study hypothesizes that TI stimulation targeting the ALIC may improve clinical symptoms in patients with TRS and may be associated with measurable changes in neuroimaging markers.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Right-handed male or female participants aged 18 to 65 years, inclusive.
- Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), established by a psychiatrist at the attending-physician level or above and confirmed by the Mini International Neuropsychiatric Interview, version 7.0.2 (MINI 7.0.2).
- Inadequate response to sequential treatment with at least two antipsychotic medications of different chemical classes, each administered at an adequate dose (≥600 mg/day chlorpromazine equivalents) for an adequate duration (≥6 consecutive weeks at a therapeutic dose).
- Stable dose of antipsychotic medication for at least 4 weeks before enrollment.
- A score of 4 (moderate) or higher on at least two of the following Positive and Negative Syndrome Scale (PANSS) items: delusions, hallucinatory behavior, suspiciousness/persecution, or unusual thought content.
- Ability to understand the study procedures, willingness to participate voluntarily and comply with the study procedures, and provision of written informed consent.
Exclusion Criteria:
- Current diagnosis of another major psychiatric disorder other than schizophrenia that, in the investigator's judgment, may confound the diagnosis of schizophrenia or interfere with the assessment of treatment efficacy or safety.
- Receipt of other neuromodulation treatments, including modified electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (rTMS), or transcranial direct current stimulation (tDCS), within the previous 3 months, or previous participation in an interventional clinical trial involving vagus nerve stimulation (VNS) or deep brain stimulation (DBS).
- A score ≥3 on Item 3 (suicide) of the 17-item Hamilton Depression Rating Scale (HAMD-17), or a score >3 on any of the following PANSS items: P4 Excitement, G14 Poor Impulse Control, P7 Hostility, or G8 Uncooperativeness.
- Contraindications to magnetic resonance imaging (MRI), including intracranial metallic implants, implanted cardiac pacemakers, or cochlear implants.
- Skull defects or fissures, or inability to tolerate stimulation-related adverse effects.
- Treatment-resistant epilepsy or other serious medical conditions that, in the investigator's judgment, may potentially affect treatment or participation in the study.
- Pregnancy.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：時間的干渉刺激
|
Participants with treatment-resistant schizophrenia will receive 130-Hz temporal interference stimulation targeting the anterior limb of the internal capsule (ALIC).
Stimulation will be delivered at a total current intensity of 4 mA for 5 consecutive days, with four 40-minute sessions per day and a 20-minute interval between sessions.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment
時間枠：Baseline to Day 5
|
Baseline to Day 5
|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 2-Week Follow-up
時間枠：Baseline to Day 14 ± 2 days after treatment completion
|
Baseline to Day 14 ± 2 days after treatment completion
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change From Baseline in PANSS Positive Symptom Subscale Score
時間枠：Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in PANSS Negative Symptom Subscale Score
時間枠：Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in PANSS General Psychopathology Subscale Score
時間枠：Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in MATRICS Consensus Cognitive Battery (MCCB) Score
時間枠：Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score
時間枠：Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in Personal and Social Performance Scale (PSP) Score
時間枠：Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
|
Change From Baseline in Clinical Global Impression (CGI) Score
時間枠：Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
Baseline to Day 5 and Day 14 ± 2 days after treatment completion
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CapitalMedicalU
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。